Targeting a novel epigenetic regulator of Hodgkin lymphoma, H2A.B, for treament of cancer

We have identified a novel key regulator of Hodgkin Lymphoma, epigenetic factor, histone H2A.B. This proposal aims to develop novel therapeutic tools that would target H2A.B and potentially provide a more specific and less toxic treatment for Hodgkin Lymphoma patients. We will use Modular Nanotransporters, a highly specific intracellular delivery system, to target H2A.B for degradation and we will use the small molecule kinase inhibitors for functional inactivation of H2A.B.